Korro to Present at the TD Cowen 45th Annual Health Care Conference

Rhea-AI Summary

Korro Bio (Nasdaq: KRRO), a clinical-stage biopharmaceutical company specializing in RNA-based genetic medicines, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The event will take place on March 4, 2025, at the Boston Marriott Copley Place.

CEO and President Ram Aiyar, Ph.D. will deliver a presentation at 11:50 a.m. ET, while COO Todd Chappell will engage in one-on-one investor meetings during the conference. Interested parties can access a live webcast of the presentation through Korro's website investor section, with a replay available for 30 days post-event.

News Market Reaction – KRRO

-3.86%

-3.86% Session move

In the trading session that priced this news, KRRO declined 3.86%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 45^th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. ET at the Boston Marriott Copley Place. Todd Chappell, Chief Operating Officer, will also participate in 1x1 investor meetings at the conference.

A live webcast of the presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days.

About Korro

Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Contact Information

Investor & Media Contact
Tim Palmer
IR@korrobio.com 

This press release was published by a CLEAR® Verified individual.

FAQ

When is Korro Bio (KRRO) presenting at the TD Cowen Health Care Conference 2025?

Korro Bio will present on Tuesday, March 4, 2025, at 11:50 a.m. ET at the Boston Marriott Copley Place.

How can investors watch Korro Bio's (KRRO) TD Cowen conference presentation?

Investors can watch the live webcast through the 'Events & Presentations' page in the Investor section of Korro's website (www.korrobio.com). A replay will be available for 30 days.

What type of genetic medicines is Korro Bio (KRRO) developing?

Korro Bio is developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases.

Who will represent Korro Bio (KRRO) at the TD Cowen Healthcare Conference?

Ram Aiyar, Ph.D., CEO and President, will present, while Todd Chappell, COO, will participate in 1x1 investor meetings.